Physician profile
Lingyi Chen
NPI 1922330844
$20,445.37
in general payments reported to CMS, 2019-2025
78 companies · $4,130 in 2025
The $4,130 reported for 2025 was more than what 79% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,973 · 2020: $713 · 2021: $2,030 · 2022: $2,982 · 2023: $5,002 · 2024: $3,614 · 2025: $4,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Honoraria: $1,024 · Consulting Fee: $825 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,608.09 |
| Honoraria | $1,023.75 |
| Consulting Fee | $825.00 |
| Education | $289.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,364.42 | 2019-2025 | Kisqali |
| Rigel Pharmaceuticals, INC. | $1,207.75 | 2021-2024 | Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $1,162.14 | 2020-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $1,050.02 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $999.35 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Pfizer INC. | $935.97 | 2019-2025 | |
| Celgene Corporation | $919.49 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $793.53 | 2019-2025 | Rybrevant, Darzalex, Erleada |
| Incyte Corporation | $734.91 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $694.54 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Amgen INC. | $656.76 | 2019-2023 | Kyprolis, Xgeva, Vectibix |
| Glaxosmithkline, LLC. | $608.05 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Exelixis INC. | $579.74 | 2019-2025 | Cabometyx |
| Astellas Pharma US INC | $528.97 | 2019-2025 | Padcev, Xospata, Xtandi |
| Genzyme Corporation | $453.13 | 2019-2025 |
Show all 78 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $427.46 | 2019-2025 | Phesgo, Tecentriq, Venclexta |
| Seagen INC. | $422.78 | 2019-2023 | Padcev, Tivdak, Adcetris |
| Karyopharm Therapeutics INC. | $399.34 | 2020-2025 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $389.57 | 2019-2025 | Opdualag, Opdivo |
| Eisai INC. | $377.87 | 2019-2025 | |
| Abbvie INC. | $338.78 | 2019-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $291.67 | 2019-2025 | Onivyde, Somatuline Depot, Tazverik |
| Gilead Sciences, INC. | $283.05 | 2021-2025 | Trodelvy |
| Inari Medical, INC. | $268.28 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $259.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.48 | 2019-2024 | Fruzaqla, Vonvendi, Ninlaro |
| Array Biopharma INC | $242.65 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Regeneron Healthcare Solutions, INC. | $237.57 | 2019-2025 | Libtayo, Lynozyfic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.08 | 2021-2025 | Gilotrif |
| Pharmacyclics LLC, An Abbvie Company | $214.53 | 2020-2023 | Imbruvica |
| Beigene USA, INC. | $201.98 | 2021-2025 | Brukinsa, Tevimbra |
| Emd Serono, INC. | $198.12 | 2019-2025 | Tepmetko |
| Epizyme, INC. | $182.54 | 2020-2022 | |
| Puma Biotechnology, INC. | $168.15 | 2019-2025 | |
| Sobi, INC | $165.41 | 2022-2025 | |
| Kite Pharma, INC. | $138.79 | 2021-2023 | Yescarta |
| Morphosys, US INC. | $127.56 | 2021-2023 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $126.44 | 2023-2025 | Monoferric, Cosela |
| Myriad Genetic Laboratories, INC. | $114.44 | 2022-2025 | Myrisk |
| G1 Therapeutics, INC. | $100.89 | 2022-2023 | Cosela |
| Beone Medicines USA, INC. | $100.54 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $94.18 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $92.92 | 2022-2025 | Fotivda |
| Legend Biotech USA INC. | $87.35 | 2024-2025 | Carvykti |
| Deciphera Pharmaceuticals INC. | $86.07 | 2021-2025 | Qinlock, Romvimza |
| Tesaro, INC. | $84.23 | 2019 | |
| Myovant Sciences INC. | $81.13 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $69.73 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $68.91 | 2022-2023 | Ultomiris |
| Spectrum Pharmaceuticals INC. | $66.19 | 2023-2025 | Rolvedon |
| Iovance Biotherapeutics, INC. | $57.95 | 2025 | Amtagvi |
| Amag Pharmaceuticals, INC. | $56.93 | 2019-2021 | |
| Pharmaessentia USA Corporation | $53.67 | 2022-2024 | Besremi |
| Mirati Therapeutics, INC. | $52.24 | 2023 | Krazati |
| Dendreon Pharmaceuticals LLC | $50.40 | 2024-2025 | Provenge |
| Alnylam Pharmaceuticals INC. | $47.23 | 2021-2023 | Givlaari |
| Geron Corporation | $40.34 | 2025 | Rytelo |
| Foundation Medicine, INC. | $34.98 | 2019 | |
| Dova Pharmaceuticals | $31.14 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $25.40 | 2024 | Sylvant |
| Sirtex Medical INC | $20.98 | 2025 | Sir-Spheres Microspheres |
| Blue Earth Diagnostics | $19.90 | 2022 | |
| Tersera Therapeutics LLC | $18.70 | 2021 | |
| Adaptive Biotechnologies Corporation | $18.48 | 2025 | Clonoseq |
| Nuvation Bio INC. | $18.14 | 2025 | Ibtrozi |
| Kyowa Kirin, INC. | $18.04 | 2025 | |
| Apellis Pharmaceuticals, INC. | $17.95 | 2023 | Empaveli |
| Horizon Therapeutics Plc | $17.94 | 2022 | |
| Taiho Oncology, INC. | $17.57 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $16.23 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.01 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.75 | 2022 | |
| Caris Mpi, INC. | $15.75 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $15.61 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.46 | 2021 | |
| Servier Pharmaceuticals LLC | $14.59 | 2022 | |
| Novocure INC. | $13.88 | 2025 | Optune Lua (Novottf-200t) |
| Azurity Pharmaceuticals, INC. | $13.77 | 2025 | Danziten, Vivimusta |
Drugs and devices associated with these payments
Enhertu $1,281Rezlidhia $1,162Tavalisse $1,162Keytruda $467Reblozyl $442Cabometyx $434Kisqali $408Imfinzi $372Lynparza $317Padcev $274Ct Thrombectomy System Kit $268Flowtriever Catheter, S $268Ojjaara $230Jaypirca $229Zejula $224Jemperli $224Lenvima $198Monjuvi $195Verzenio $192Rybrevant $187Jakafi $187Venclexta $186Xpovio $168Brukinsa $168Braftovi $164Xtandi $160Orgovyx $155Onivyde $150Libtayo $149Retevmo $148Lorbrena $143Fabhalta $143Opdualag $128Pluvicto $126Gilotrif $125Sarclisa $118Scemblix $116Phesgo $114Ibrance $112Mektovi $112Monoferric $112Piqray $109Trodelvy $109Darzalex $108Myrisk $99.53Talzenna $98.83Tecentriq $98.17Opdivo $97.77Carvykti $96.43Akeega $92.63Erleada $92.63Imbruvica $88.06Vonjo $86.59Inlyta $85.00Elahere $83.49Welireg $82.45Promacta $82.03Fruzaqla $76.08Xospata $75.43Fotivda $73.89Xalkori $72.65Tukysa $70.31Cosela $70.26Somatuline Depot $67.50Rolvedon $66.19Qinlock $65.24Tevimbra $64.91Stivarga $64.30Kyprolis $62.22Pomalyst $61.76Amtagvi $57.95Tazverik $57.84Adcetris $54.96Elrexfio $53.90Balversa $52.73Tecvayli $52.57Krazati $52.24Alecensa $51.84Romvimza $51.32Provenge $50.40Perjeta $44.93Nplate $44.69Vectibix $44.69Xgeva $44.69Epkinly $43.91Lunsumio $42.81Nubeqa $42.34Xofigo $42.34Vitrakvi $42.11Zynyz $41.05Rytelo $40.34Polivy $39.35Vonvendi $39.03Yescarta $38.92Tepmetko $38.43Blincyto $37.73Besremi $36.20Tivdak $35.50Itovebi $35.11Tasigna $32.96
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingyi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.